Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis
American Journal of Psychiatry
Fecha de publicación: 18 de febrero de 2021
Autores: Giovanni Ostuzzi, M.D., Ph.D., Federico Bertolini, M.D., Cinzia Del Giovane, Ph.D., Federico Tedeschi, Ph.D., Chiara Bovo, M.D., Chiara Gastaldon, M.D., Michela Nosé, M.D., Ph.D., Filippo Ogheri, M.D., Davide Papola, M.D., Marianna Purgato, Psy.D., Ph.D., Giulia Turrini, Psy.D., Christoph U. Correll, M.D., Corrado Barbui, M.D.
DOI: https://doi.org/10.1176/appi.ajp.2020.20071120
Background: This study compared relapse prevention and acceptability of long-acting injectable (LAI) antipsychotics in the maintenance treatment of adults with nonaffective psychoses. Methods: The authors searched MEDLINE, Embase, PsycINFO, CINAHL, CENTRAL, and online registers for randomized controlled trials published until June 2020. Relative risks and standardized mean differences were pooled using random-effects pairwise and network meta-analysis. The primary outcomes were relapse rate and all-cause discontinuation (“acceptability”). The quality of included studies was rated with the Cochrane Risk of Bias tool, and the certainty of pooled estimates was measured with GRADE (Grading of Recommendations Assessment, Development, and Evaluation).
